Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data.

Tom Konikoff,Henit Yanai,Dror Libchik,Irit Avni-Biron,Yifat Snir, Hagar Banai,Yelena Broytman,Iris Dotan,Jacob E Ollech

Journal of clinical medicine（2023）

引用 0|浏览2

暂无评分

摘要

VDZ showed significantly longer DS in treatment-naïve patients with UC compared to IFX, also when adjusted for disease severity. There was no difference in DS between VDZ and IFX in treatment-experienced patients and patients switching from one drug to another. VDZ may be a suitable first-line treatment for biologic-naïve patients with moderate-to-severe UC.

查看译文

关键词

longer drug sustainability,infliximab,moderate-to-severe,long-term,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要